TEAM
Sotirios Stergiopoulos, MD, MBEE, FACP
President & CEO, Founder
​Harvard Medical School, Bayer, Novartis, Celgene, CMO of Ipsen​
-
Chief Medical Officer, SVP and Head of Global Medical Affairs at Ipsen
-
Vice President and Head of Global Medical Affairs Oncology for Baxalta Inc and Shire & roles in medical affairs and clinical development at Bayer Pharmaceuticals, Novartis Pharmaceuticals and Celgene Corporation
-
Trained in Internal Medicine and Cancer Genetics from NIH, Albert Einstein College of Medicine and Harvard Medical School
-
Masters of Biotechnology Enerprise and Entrepreneurship from Johns Hopkins University
Edward Painter, MBA
Chairman & CIO, Founder
Research and Biotech focused capital markets with Goldman Sachs, Credit Suisse & UBS​​
-
MBA from University of Illinois at Urbana-Champaign
-
Former VP at UBS, Oppenheimer & Co., Credit Suisse, and Kidder Peabody
-
Former analyst at Goldman Sachs and Salomon Brothers
-
30 years of experience in finance
-
Has worked extensively with biotech companies in financing and investment decisions
Sridhar Vempati
Chief Strategy Officer & Executive VP of R&D, Founder
Harvard University Postdoc Leukemia Research, BD Ironwood and Rafael Pharma​
-
PhD in Human Biology from Ludwig-Maximilians University
-
MBA from Boston University
-
Postdoctoral research at Harvard University in leukemia and the target of AO-001
-
Authored several articles in oncology in leading publications
-
Biotechnology industry analyst experience at Jeffries LLC
Chaemin Lim, PhD
Chief Scientific Officer
Medicinal and Computational Chemist. Seoul National University, University of Pittsburgh, UPCDC ​
-
PhD in Synthetic and Medicinal Chemistry from the Seoul National University
-
Postdoctoral research in Chemistry from the University of Pittsburgh
-
Extensive research experience in synthetic organic chemistry and drug discovery covering multiple therapeutic areas
-
Co-authored 20 SCI papers and 9 patent applications as a co-inventor
-
Has contributed to drug discovery and development projects ranging from early development stages through to preclinical trials particularly using in silico drug design tools